Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 6/20 | 0.58 |
| ▸ | MMP2 | P08253 | 6/20 | 0.58 |
| ▸ | MMP3 | P08254 | 6/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7205132 | 0.99 | MMP1 (0.57) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL9146938 | 0.90 | LTA4H (0.50) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL9146946 | 0.90 | LTA4H (0.50) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL4960993 | 0.85 | MMP1 (0.44) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL27182937 | 0.85 | MMP1 (0.44) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL30799798 | 0.82 | LTA4H (0.49) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL26176491 | 0.82 | MMP1 (0.49) | MMP1MMP2MMP3CPB2CHRNB2 | |
| SCHEMBL27182830 | 0.81 | CTSK (0.47) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL22827993 | 0.80 | MMP1 (0.53) | MMP1MMP2MMP3LTA4HCPB2 | |
| SCHEMBL13735669 | 0.79 | MMP1 (0.47) | MMP1MMP2MMP3CPB2GRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6384272-B2 | FORMATION OF AMMONIUM SALT OF (ALPHA-ASPARTYL)PHENYLALANINE BY AMIDATION OF ESTER OF (ALPHA-ASPARTYL)PHENYLALANINE, THEN (ALPHA-ASPARTYL)-BETA-CYCLOHEXYLALANINAMIDE IS OBTAINED BY CATALYTIC HYDROGENATION | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | claimed |
| EP-1084138-B1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | AVENTIS PHARMA SA (FR) | 2002-01-30 | — | — | EP | claimed |
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | AVENTIS PHARMA S.A. (FR) | 2001-10-25 | — | — | US | claimed |
| EP-1084138-A1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | Aventis Pharma S.A. (FR) | 2001-03-21 | — | — | EP | claimed |
| WO-1999064443-A1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | claimed |
| EP-1030831-A4 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARM PROD INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6384272-B2 | FORMATION OF AMMONIUM SALT OF (ALPHA-ASPARTYL)PHENYLALANINE BY AMIDATION OF ESTER OF (ALPHA-ASPARTYL)PHENYLALANINE, THEN (ALPHA-ASPARTYL)-BETA-CYCLOHEXYLALANINAMIDE IS OBTAINED BY CATALYTIC HYDROGENATION | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| US-6384272-B2 | FORMATION OF AMMONIUM SALT OF (ALPHA-ASPARTYL)PHENYLALANINE BY AMIDATION OF ESTER OF (ALPHA-ASPARTYL)PHENYLALANINE, THEN (ALPHA-ASPARTYL)-BETA-CYCLOHEXYLALANINAMIDE IS OBTAINED BY CATALYTIC HYDROGENATION | AVENTIS PHARMA S.A. (FR) | 2002-05-07 | — | — | US | disclosed |
| EP-1084138-B1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | AVENTIS PHARMA SA (FR) | 2002-01-30 | — | — | EP | disclosed |
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | AVENTIS PHARMA S.A. (FR) | 2001-10-25 | — | — | US | disclosed |
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | AVENTIS PHARMA S.A. (FR) | 2001-10-25 | — | — | US | disclosed |
| EP-1084138-A1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | Aventis Pharma S.A. (FR) | 2001-03-21 | — | — | EP | disclosed |
| US-6180759-B1 | PREPARING AZACYCLOALKANOYLPSEUDOTETRAPEPTIDES COMPRISING COUPLING A DIPEPTIDE WITH A PSEUDODIPEPTIDE; FOR EXAMPLE, N-(N-ETHYL-N-(1-OXO-4-(4-PIPERIDINYL)BUTYL)GLYCYL)-(L)-ALPHA-ASPARTYL-3 -CYCLOHEXYL-(L)-ALANINEAMIDE; USE AS ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | disclosed |
| EP-1030831-A1 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999064443-A1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064443-A1 | METHOD FOR PREPARING ASPARTYL CYCLOHEXYLALANINAMIDE | AVENTIS PHARMA S.A. (FR) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999019294-A1 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARMACEUTICALS PRODUCTS INC. LEGAL/PATENTS (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034460-A1 | Method for preparing aspartylcyclohexyla laninamide | ASNS, DNPEP, ANPEP | MMP1 1030/4885MMP2 523/4885MMP3 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.